There's more political pressure on governors to contain costs and influence healthcare delivery. An industry think tank aims to tackle cost and quality for state leaders.
The State Health Care Cost Containment Commission-an industry think tank-plans to release its first toolkit in November, outlining six broad strategies with 35 to 40 potential actions that states can use to enhance quality and reduce costs.
Ray Scheppach, commission director and former executive director of the National Governors Assn., says the report is different from prevailing publications because it concentrates on changes at the state rather than federal level.
“It’s surprising,” Scheppach says. “States have almost all of the policy levers. It’s amazing nobody focused on state actions before.”
While declining to mention specific recommendations until the commission finalizes the report, Scheppach says the members-a bipartisan group of former governors, and health system and health plan CEOs-easily reached consensus on tactics that governors could employ. For example, he says, they tout the convening power of governors to enact change by getting stakeholders around a table to discuss issues, such as how to change the payment system in a state.
“Everybody agrees that fee-for-service is not very good, creates incentives for unproductive care and that we probably need to move toward a capitated system where provides share the risk,” he says.
He said they also suggest that states need to enact changes because healthcare needs to be tailored to the needs of individual states.
Scheppach notes that Medicare covers approximately 50 million members while states will cover around 100 million, comprised of 70 million in Medicaid, 10 million to 15 million in state healthcare exchanges and 4 million state employees. By sheer numbers, the impact states can have is larger than the federal government.
States also have oversight related to malpractice law and scope of practice that helps them influence the healthcare process. Scheppach says the commission also focuses on states because of “the sense that the federal government is locked up in the politics around healthcare and the idea of them doing anything is limited.”
He says that by the time the commission report is released, and the major provisions of the Patient Protection and Affordable Care Act (PPACA) take effect, healthcare may become an even larger election issue in 2014, when 36 governor seats are up for election.
“There is a huge unknown about how many people with serious medical conditions will come into the system and what will happen to cost, where the pendulum will shift,” he says about PPACA. “There will be a real shakeout over several years.”
But, he says the commission members are optimistic that their tools can make a difference.
“We feel we now know how to make the change and what’s going to help in terms of both quality and cost,” he says.
In the next three to five years, he expects smaller, innovative states-perhaps Oregon, Utah, Vermont or Connecticut-to serve as “prairie fires” and lead the way. As they achieve success, Scheppach says, controlled healthcare costs will become part of the economic development calculation for firms selecting a place to launch or relocate.
“You’re going to end up with more political pressure on governors to get into this area,” he says. “Are we going to transform the United States overnight? No. But, we’ve got enough experience in looking at how to do things at the state level. We believe we have the right answers, but a number of states have to go and show it.”
The commission’s goal is to create practical solutions for states to manage today’s crushing healthcare costs.
States are in a situation where they must cut other programs such as education and infrastructure to maintain healthcare services.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Opzelura May Reduce Need for Other Treatments in Atopic Dermatitis | AAD 2025
March 11th 2025Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics during the 12 months after treatment with the topical nonsteroidal, finds study at American Academy of Dermatology Association annual meeting.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Supporting Patients with Type 1 Diabetes Through Education, Technology and Transparency
March 10th 2025Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps patients with type 1 diabetes effectively use glucose monitors and insulin pumps by providing clear guidance and troubleshooting support, recognizing that even minor errors in management can have significant health consequences.
Read More
Melanoma Treatment Advances Now Crossing into Other Skin Cancers
March 10th 2025Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with advanced basal cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma, which is a rare and aggressive type of skin cancer.
Read More